FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...
Geron (GERN) announced results from an oral presentation at the 66th American Society of Hematology, or ASH, annual meeting, reporting Phase 1 findings from the two-part IMproveMF study. The safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results